The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Illumina to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Monday, January 28, 2013

Tuesday, January 15, 2013

Illumina to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Monday, January 28, 201306:30 EST Tuesday, January 15, 2013 SAN DIEGO (Business Wire) -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2012 following the close of market on Monday, January 28, 2013. On the same day, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) Jay Flatley, President and Chief Executive Officer; Marc Stapley, Senior Vice President and Chief Financial Officer; and Christian Henry, Senior Vice President and General Manager, Genomic Solutions will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on Monday, January 28, 2013. Interested parties may listen to the call by dialing 888-679-8035 (passcode: 35493315), or if outside North America, by dialing +1-617-213-4848 (passcode: 35493315). Individuals may access the live teleconference in the Investor Relations section of Illumina's web site under the “Company” tab at www.illumina.com. A replay of the conference call will be available from 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time) on January 28, 2013 through February 4, 2013 by dialing 888-286-8010 (passcode: 76555573), or if outside North America, by dialing +1-617-801-6888 (passcode: 76555573). About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Illumina, Inc.Investors:Rebecca Chambers, 858-255-5243rchambers@illumina.comorMedia:Jennifer Temple, 858-882-6822pr@illumina.com